Stryker (NYSE:SYK) Downgraded by Canaccord Genuity Group to Hold

Key Points

• Canaccord Genuity downgraded Stryker from “Buy” to “Hold” and set a $300 price target, implying approximately 3.57% downside from the reported share price.
• Stryker’s latest quarter showed 7.6% year-over-year revenue growth to $6.52 billion, but both revenue and adjusted EPS of $3.52 fell short of analyst expectations. The company also lowered its 2026 organic sales-growth and adjusted EPS guidance.
• Despite the downgrade, analysts collectively maintain a “Moderate Buy” consensus with a $362.76 target price; however, insiders sold approximately $118.2 million of stock over the past 90 days.

Stryker (NYSE:SYK - Get Free Report) was downgraded by analysts at Canaccord Genuity Group from a "buy" rating to a "hold" rating in a research report issued to clients and investors on Friday, MarketBeat Ratings reports. They currently have a $300.00 target price on the medical technology company's stock. Canaccord Genuity Group's price objective would suggest a potential downside of 3.57% from the company's current price.

A number of other brokerages have also issued reports on SYK. Wall Street Zen lowered Stryker from a "buy" rating to a "hold" rating in a research note on Saturday, October 3rd. Evercore set a $350.00 price target on Stryker in a research note on Monday, July 6th. Argus set a $370.00 price objective on Stryker in a report on Thursday, July 9th. Stifel Nicolaus reduced their price objective on Stryker from $360.00 to $330.00 and set a "buy" rating for the company in a research note on Wednesday, September 30th. Finally, BMO Capital Markets reaffirmed an "outperform" rating and set a $317.00 target price on shares of Stryker in a report on Wednesday, September 9th. One investment analyst has rated the stock with a Strong Buy rating, sixteen have given a Buy rating and seven have issued a Hold rating to the stock. According to MarketBeat, the stock presently has an average rating of "Moderate Buy" and a consensus target price of $362.76.

Stryker Stock Up 2.3%

NYSE:SYK opened at $311.12 on Friday. Stryker has a 1-year low of $267.00 and a 1-year high of $389.33. The company has a 50-day moving average of $293.56 and a 200 day moving average of $324.86. The firm has a market cap of $119.34 billion, a PE ratio of 32.24, a price-to-earnings-growth ratio of 1.96 and a beta of 0.78. The company has a debt-to-equity ratio of 0.59, a current ratio of 2.16 and a quick ratio of 1.33.

Stryker (NYSE:SYK - Get Free Report) last posted its earnings results on Thursday, October 29th. The medical technology company reported $3.52 earnings per share (EPS) for the quarter, missing the consensus estimate of $3.55 by ($0.03). The company had revenue of $6.52 billion during the quarter, compared to analysts' expectations of $6.62 billion. Stryker had a net margin of 14.43% and a return on equity of 23.63%. Stryker's revenue for the quarter was up 7.6% on a year-over-year basis. During the same quarter last year, the firm earned $3.19 EPS. As a group, research analysts anticipate that Stryker will post 14.93 EPS for the current fiscal year.

Insider Buying and Selling at Stryker

In other news, insider Debra King sold 826 shares of Stryker stock in a transaction dated Tuesday, August 18th. The shares were sold at an average price of $336.30, for a total value of $277,783.80. Following the sale, the insider owned 6,210 shares in the company, valued at $2,088,423. This trade represents a 11.74% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, Director Ronda Stryker sold 300,000 shares of the business's stock in a transaction dated Tuesday, August 18th. The stock was sold at an average price of $335.90, for a total transaction of $100,770,000.00. Following the sale, the director directly owned 2,301,375 shares of the company's stock, valued at $773,031,862.50. This represents a 11.53% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold a total of 351,267 shares of company stock valued at $118,197,701 over the last ninety days. Corporate insiders own 4.60% of the company's stock.

Hedge Funds Weigh In On Stryker

A number of hedge funds have recently made changes to their positions in SYK. Gables Capital Management Inc. acquired a new position in Stryker in the 2nd quarter valued at $25,000. Kilter Group LLC purchased a new position in Stryker in the 2nd quarter valued at $25,000. Cornerstone Financial Management LLC lifted its holdings in Stryker by 66.0% in the 2nd quarter. Cornerstone Financial Management LLC now owns 78 shares of the medical technology company's stock valued at $25,000 after purchasing an additional 31 shares in the last quarter. Highland Investment Advisors LLC acquired a new stake in Stryker during the 2nd quarter worth $25,000. Finally, Compass Financial Management LLC acquired a new stake in Stryker during the 2nd quarter worth $27,000. Institutional investors and hedge funds own 77.09% of the company's stock.

More Stryker News

Here are the key news stories impacting Stryker this week:

• Positive Sentiment: Third-quarter revenue increased approximately 7.6%–7.7% year over year to $6.52 billion, while adjusted EPS rose to $3.52 from $3.19 a year earlier. Stryker reports third quarter 2026 operating results
• Neutral Sentiment: Management is navigating manufacturing constraints in the vascular business and lingering operational effects from the cybersecurity incident disclosed in March. A new CEO is also taking over as the company reassesses its growth trajectory, making the 2027 starting point a key investor focus. Stryker’s Guidance Cut Rattles Investors
• Negative Sentiment: Third-quarter adjusted EPS of $3.52 missed the roughly $3.55–$3.56 analyst consensus, and revenue of $6.52 billion fell short of the $6.62 billion estimate. The earnings and sales misses triggered a significant selloff. Stryker Q3 2026 earnings revenue and EPS miss
• Negative Sentiment: Stryker lowered its 2026 organic net sales growth forecast to 6.5%–7.0% from 8.3%–9.3%, while adjusted EPS guidance moved to $14.80–$14.90 from $14.95–$15.10. The larger sales reduction suggests demand, supply, or execution concerns beyond a one-quarter earnings miss. Stryker Slides After Lowering 2026 Outlook
• Negative Sentiment: Analysts subsequently cut their forecasts and price targets, reinforcing concerns about slower growth, margin pressure, and the company’s ability to regain momentum in 2027. Stryker Analysts Cut Their Forecasts

About Stryker

Stryker Corporation NYSE: SYK is a global medical technology company that develops and manufactures products used by healthcare providers in hospitals, surgical centers and other clinical settings. Its offerings are designed to support orthopaedic procedures, surgery, emergency care, neurovascular treatment and patient handling.

The company's product portfolio includes orthopaedic implants and instruments, products for trauma and spine procedures, surgical equipment, endoscopy systems, patient beds and stretchers, emergency medical equipment, and neurovascular devices used in the treatment of conditions such as stroke.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.